Pharmacogenetic testing in the face of unclear clinical efficacy: Lessons from cytochrome P450 2D6 for tamoxifen

E-ISSN： 1097-0142|119|20|3703-3709

ISSN： 0008-543x

Source： CANCER, Vol.119, Iss.20, 2013-10, pp. : 3703-3709

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Meaningful Use and Clinical Utility of Preemptive Pharmacogenetic Testing: (Re)View From a CYP2D6 Poor Metabolizer

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 97, Iss. 2, 2015-02 ,pp. : 119-121

John Wiley & Sons Inc

Access to resources Recommend Favorite

Are health technology assessments of pharmacogenetic tests feasible? A case study of CYP2D6 testing in the treatment of breast cancer with tamoxifen

By Fleeman Nigel Payne Katherine Newman William G Howell Sacha J Boland Angela Oyee James Saborido Carlos Martin Santander Ana Fernández Dickson Rumona

Personalized Medicine, Vol. 10, Iss. 6, 2013-08 ,pp. : 601-611

Future Medicine

Access to resources Recommend Favorite

Genotyping of the cytochrome P450 2D6 4469 C>T polymorphism using SimpleProbes™

By Nielsen K. A. Hansen E. Lyders Gille S.

Scandinavian Journal of Clinical and Laboratory Investigation, Vol. 67, Iss. 3, 2007-01 ,pp. : 280-290

Informa Healthcare

Access to resources Recommend Favorite

Genetic Transmission of Cytochrome P450 2D6 (CYP2D6) Ultrarapid Metabolism: Implications for Breastfeeding Women taking Codeine

Current Drug Safety, Vol. 6, Iss. 1, 2011-02 ,pp. : 36-39

Bentham Science Publishers

Access to resources Recommend Favorite

Polymorphism in CYP2D6 and CYP2C19, members of the cytochrome P450 mixed‐function oxidase system, in the metabolism of psychotropic drugs

JOURNAL OF INTERNAL MEDICINE, Vol. 277, Iss. 2, 2015-02 ,pp. : 167-177

John Wiley & Sons Inc

Access to resources Recommend Favorite